Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160013/S023

Organ Care System (OCS) Lung System

TransMedics, Inc. · Decision date Oct 28, 2026

MEDTECHLEDGER EXPLANATIONP160013/S023

What did the FDA decide?

FDA records a 30-day notice supplement, P160013/S023, for the Organ Care System (OCS™) Lung System, with decision OK30 dated 2026-10-28. The stated change is "a change in supplier and mold transfer of the bellows, a component of the OCS Lung System." The notice is filed under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The product code is listed as QBA, and the applicant is TransMedics, Inc.

The identifier ties this supplement to the original PMA P160013; the notice covers a supplier change and mold transfer for one named part rather than an approval of the full system. The supplied fields do not identify the old or new supplier, describe the mold transfer, or provide verification data, so no conclusion about safety or clinical effect follows from the notice itself. The specialty fields read Gastroenterology, Urology, while the device category describes donor lung preservation, an inconsistency the record does not explain.

FDA approval order statement

a change in supplier and mold transfer of the bellows, a component of the OCS Lung System
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160013/S023
Regulatory pathway
PMA supplement
Product code
QBA
Decision code
OK30
Decision date
Oct 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic machine perfusion system for the preservation of standard criteria donor lungs prior to transplantation.

Product code
QBA
FDA device class
3

For the original device and its historical approval scope, see PMA P160013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160013 · Original PMA

    Organ Care System (OCS) Lung System

  2. P160013/S023 received

    Application receipt date recorded by FDA.

  3. P160013/S023 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P160013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160013

Product / regulatory recordCompanyPathwayDecision dateSource
TransMedics, Inc.PMA approvalMar 22, 2018FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

TransMedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
200 Minuteman Rd., Suite 302, Andover, MA, 01810

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records